Market Cap 12.22B
Revenue (ttm) 1.19B
Net Income (ttm) 14.01M
EPS (ttm) N/A
PE Ratio 85.79
Forward PE 82.55
Profit Margin 1.17%
Debt to Equity Ratio 0.00
Volume 419,100
Avg Vol 457,584
Day's Range N/A - N/A
Shares Out 39.16M
Stochastic %K 90%
Beta 0.66
Analysts Strong Sell
Price Target $317.24

Company Profile

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under...

Industry: Medical Devices
Sector: Healthcare
Phone: 510 748 3200
Address:
One Penumbra Place, Alameda, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 11:35 PM
Actionable Trade Alert for $PEN: Market Context: $PEN is currently trading at $311.97, close to its 60D high of $313.27. The RSI at 68.88 indicates it is nearing overbought territory, suggesting caution. However, the strong upward movement is supported by the MA30 (277.24) and MA50 (266.96), indicating a bullish trend. Directional Bias: The price is above both the MA30 and MA50, signaling a bullish trend. However, the RSI suggests a potential pullback could occur soon. Trade Plan: - Suggested Entry: $310.00 - Stop Loss: $295.00 (approx. 4.9% below entry) - Take Profit Targets: 1. $320.00 (2.58% gain) 2. $325.00 (4.52% gain) 3. $365.00 (17.00% gain) Rationale: The targets are based on resistance levels and the potential for continued upward momentum. Monitor RSI for signs of reversal. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 11 at 2:03 PM
Citigroup has updated their rating for Penumbra ( $PEN ) to Buy with a price target of 350.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 3:39 AM
Actionable Trade Alert for $PEN: Market Context: $PEN is currently trading at $287.14, showing bullish momentum with an RSI of 56.57, indicating potential for upward movement. The price is above both the 30-day MA (272.37) and the 50-day MA (264.72), suggesting a strong bullish trend. Directional Bias: The bullish sentiment is supported by the price being closer to the 60-day high of $303.00, while the RSI indicates there is still room for upward movement before reaching overbought territory. Trade Plan: - Suggested Entry: $287.14 - Stop Loss: $274.32 (approx. 4.5% below entry) - Take Profit Targets: 1. $300.00 (4.5% gain) 2. $310.00 (7.9% gain) 3. $336.00 (17% gain) With a well-defined stop loss and multiple take profit targets, this trade presents a solid risk-reward ratio. Monitor price action closely for optimal execution. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 8 at 11:27 PM
Actionable Trade Alert for $PEN: Market Context: $PEN is currently trading at $294.78, exhibiting bullish momentum as indicated by an RSI of 63.21, suggesting it is nearing overbought territory but still has room for growth. The stock is above its 30-day moving average (MA30) of 271.06 and 50-day moving average (MA50) of 264.01, indicating a strong upward trend. Directional Bias: The recent price action is positive, with the stock approaching its 60-day high of $303.00. Given the current metrics, we anticipate a continuation of this upward trend. Trade Plan: - Suggested Entry: $295.00 - Stop Loss: $284.00 (10% below entry) - Take Profit Targets: 1. $305.00 (3.39% gain) 2. $315.00 (6.78% gain) 3. $345.00 (17% gain) This plan aims for a minimum 17% ROI on the third target, capitalizing on the stock's upward momentum. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 2:27 AM
Actionable Trade Alert for $PEN: Market Context: $PEN is currently trading at $294.72, showing strong momentum with an RSI of 65.18, indicating it is nearing overbought territory. The price is above key moving averages (MA30 at 268.1 and MA50 at 262.15), suggesting bullish sentiment. The recent 60D high of $301.22 provides a critical resistance level, while the low of $221.26 indicates a strong support zone. Directional Bias: The upward trend is supported by the price being above the MAs and the recent high. However, caution is advised due to the high RSI, which may indicate a potential pullback. Trade Plan: - Suggested Entry: $295.00 - Stop Loss: $286.00 (below MA30) - Take Profit Targets: 1. $302.00 (2.4% ROI) 2. $310.00 (5.2% ROI) 3. $345.00 (17% ROI) This trade plan positions for a breakout above recent highs while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 10:01 PM
Actionable Trade Alert for $PEN: Market Context: $PEN is currently trading at $294.72, showing strong momentum with an RSI of 65.18, indicating it is nearing overbought territory. The price is above key moving averages (MA30 at 268.1 and MA50 at 262.15), suggesting bullish sentiment. The recent 60D high of $301.22 provides a critical resistance level, while the low of $221.26 indicates a strong support zone. Directional Bias: The upward trend is supported by the price being above the MAs and the recent high. However, caution is advised due to the high RSI, which may indicate a potential pullback. Trade Plan: - Suggested Entry: $295.00 - Stop Loss: $286.00 (below MA30) - Take Profit Targets: 1. $302.00 (2.4% ROI) 2. $310.00 (5.2% ROI) 3. $345.00 (17% ROI) This trade plan positions for a breakout above recent highs while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 4 at 2:37 AM
$PEN Current Stock Price: $285.75 Contracts to trade: $290 PEN Dec 19 2025 Call Entry: $4.40 Exit: $8.69 ROI: 97% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Doozio
Doozio Nov. 30 at 12:06 AM
failed monthly Mac D 🐑! Use that $PEN n ✍️ it down. Or ⬆️. 🐒🍌🧠⏰♾️
0 · Reply
Wigglyick
Wigglyick Nov. 29 at 11:10 PM
$PEN Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device system. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA. Penumbra popped after it’s Q3 ER. On the weekly it’s golden crossed and the daily is heading that way. They gave good guidance and are still in a long term uptrend. No position.
1 · Reply
123rs123
123rs123 Nov. 27 at 4:48 AM
$PEN Called it. I love this company but unfortunately as soon as it touches 300, it’s a short. I have sold my position and initiated a short at 301
1 · Reply
Latest News on PEN
Penumbra, Inc. (PEN) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 7:31 PM EST - 5 weeks ago

Penumbra, Inc. (PEN) Q3 2025 Earnings Call Transcript


Penumbra, Inc. Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 4:05 PM EST - 5 weeks ago

Penumbra, Inc. Reports Third Quarter 2025 Financial Results


Penumbra, Inc. Names Shruthi Narayan as Company President

Aug 27, 2025, 9:00 AM EDT - 3 months ago

Penumbra, Inc. Names Shruthi Narayan as Company President


Penumbra, Inc. to Present at Upcoming Investor Conferences

Aug 20, 2025, 4:30 PM EDT - 4 months ago

Penumbra, Inc. to Present at Upcoming Investor Conferences


Penumbra (PEN) Q2 Revenue Jumps 13%

Jul 30, 2025, 3:42 PM EDT - 4 months ago

Penumbra (PEN) Q2 Revenue Jumps 13%


Penumbra, Inc. (PEN) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 9:04 PM EDT - 4 months ago

Penumbra, Inc. (PEN) Q2 2025 Earnings Call Transcript


Penumbra, Inc. Reports Second Quarter 2025 Financial Results

Jul 29, 2025, 4:05 PM EDT - 4 months ago

Penumbra, Inc. Reports Second Quarter 2025 Financial Results


Penumbra, Inc. (PEN) Q1 2025 Earnings Call Transcript

Apr 23, 2025, 8:15 PM EDT - 8 months ago

Penumbra, Inc. (PEN) Q1 2025 Earnings Call Transcript


Penumbra, Inc. Reports First Quarter 2025 Financial Results

Apr 23, 2025, 4:05 PM EDT - 8 months ago

Penumbra, Inc. Reports First Quarter 2025 Financial Results


Penumbra, Inc. (PEN) Q4 2024 Earnings Call Transcript

Feb 18, 2025, 11:04 PM EST - 10 months ago

Penumbra, Inc. (PEN) Q4 2024 Earnings Call Transcript


Penumbra, Inc. (PEN) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 11:45 PM EDT - 1 year ago

Penumbra, Inc. (PEN) Q3 2024 Earnings Call Transcript


Penumbra, Inc. Reports Third Quarter 2024 Financial Results

Oct 30, 2024, 4:05 PM EDT - 1 year ago

Penumbra, Inc. Reports Third Quarter 2024 Financial Results


Why Penumbra Stock Zoomed 4% Higher Today

Oct 14, 2024, 6:20 PM EDT - 1 year ago

Why Penumbra Stock Zoomed 4% Higher Today


Why Penumbra Stock Zoomed Nearly 5% Higher Today

Sep 18, 2024, 6:29 PM EDT - 1 year ago

Why Penumbra Stock Zoomed Nearly 5% Higher Today


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 11:35 PM
Actionable Trade Alert for $PEN: Market Context: $PEN is currently trading at $311.97, close to its 60D high of $313.27. The RSI at 68.88 indicates it is nearing overbought territory, suggesting caution. However, the strong upward movement is supported by the MA30 (277.24) and MA50 (266.96), indicating a bullish trend. Directional Bias: The price is above both the MA30 and MA50, signaling a bullish trend. However, the RSI suggests a potential pullback could occur soon. Trade Plan: - Suggested Entry: $310.00 - Stop Loss: $295.00 (approx. 4.9% below entry) - Take Profit Targets: 1. $320.00 (2.58% gain) 2. $325.00 (4.52% gain) 3. $365.00 (17.00% gain) Rationale: The targets are based on resistance levels and the potential for continued upward momentum. Monitor RSI for signs of reversal. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Dec. 11 at 2:03 PM
Citigroup has updated their rating for Penumbra ( $PEN ) to Buy with a price target of 350.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 3:39 AM
Actionable Trade Alert for $PEN: Market Context: $PEN is currently trading at $287.14, showing bullish momentum with an RSI of 56.57, indicating potential for upward movement. The price is above both the 30-day MA (272.37) and the 50-day MA (264.72), suggesting a strong bullish trend. Directional Bias: The bullish sentiment is supported by the price being closer to the 60-day high of $303.00, while the RSI indicates there is still room for upward movement before reaching overbought territory. Trade Plan: - Suggested Entry: $287.14 - Stop Loss: $274.32 (approx. 4.5% below entry) - Take Profit Targets: 1. $300.00 (4.5% gain) 2. $310.00 (7.9% gain) 3. $336.00 (17% gain) With a well-defined stop loss and multiple take profit targets, this trade presents a solid risk-reward ratio. Monitor price action closely for optimal execution. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 8 at 11:27 PM
Actionable Trade Alert for $PEN: Market Context: $PEN is currently trading at $294.78, exhibiting bullish momentum as indicated by an RSI of 63.21, suggesting it is nearing overbought territory but still has room for growth. The stock is above its 30-day moving average (MA30) of 271.06 and 50-day moving average (MA50) of 264.01, indicating a strong upward trend. Directional Bias: The recent price action is positive, with the stock approaching its 60-day high of $303.00. Given the current metrics, we anticipate a continuation of this upward trend. Trade Plan: - Suggested Entry: $295.00 - Stop Loss: $284.00 (10% below entry) - Take Profit Targets: 1. $305.00 (3.39% gain) 2. $315.00 (6.78% gain) 3. $345.00 (17% gain) This plan aims for a minimum 17% ROI on the third target, capitalizing on the stock's upward momentum. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 2:27 AM
Actionable Trade Alert for $PEN: Market Context: $PEN is currently trading at $294.72, showing strong momentum with an RSI of 65.18, indicating it is nearing overbought territory. The price is above key moving averages (MA30 at 268.1 and MA50 at 262.15), suggesting bullish sentiment. The recent 60D high of $301.22 provides a critical resistance level, while the low of $221.26 indicates a strong support zone. Directional Bias: The upward trend is supported by the price being above the MAs and the recent high. However, caution is advised due to the high RSI, which may indicate a potential pullback. Trade Plan: - Suggested Entry: $295.00 - Stop Loss: $286.00 (below MA30) - Take Profit Targets: 1. $302.00 (2.4% ROI) 2. $310.00 (5.2% ROI) 3. $345.00 (17% ROI) This trade plan positions for a breakout above recent highs while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 10:01 PM
Actionable Trade Alert for $PEN: Market Context: $PEN is currently trading at $294.72, showing strong momentum with an RSI of 65.18, indicating it is nearing overbought territory. The price is above key moving averages (MA30 at 268.1 and MA50 at 262.15), suggesting bullish sentiment. The recent 60D high of $301.22 provides a critical resistance level, while the low of $221.26 indicates a strong support zone. Directional Bias: The upward trend is supported by the price being above the MAs and the recent high. However, caution is advised due to the high RSI, which may indicate a potential pullback. Trade Plan: - Suggested Entry: $295.00 - Stop Loss: $286.00 (below MA30) - Take Profit Targets: 1. $302.00 (2.4% ROI) 2. $310.00 (5.2% ROI) 3. $345.00 (17% ROI) This trade plan positions for a breakout above recent highs while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 4 at 2:37 AM
$PEN Current Stock Price: $285.75 Contracts to trade: $290 PEN Dec 19 2025 Call Entry: $4.40 Exit: $8.69 ROI: 97% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Doozio
Doozio Nov. 30 at 12:06 AM
failed monthly Mac D 🐑! Use that $PEN n ✍️ it down. Or ⬆️. 🐒🍌🧠⏰♾️
0 · Reply
Wigglyick
Wigglyick Nov. 29 at 11:10 PM
$PEN Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device system. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA. Penumbra popped after it’s Q3 ER. On the weekly it’s golden crossed and the daily is heading that way. They gave good guidance and are still in a long term uptrend. No position.
1 · Reply
123rs123
123rs123 Nov. 27 at 4:48 AM
$PEN Called it. I love this company but unfortunately as soon as it touches 300, it’s a short. I have sold my position and initiated a short at 301
1 · Reply
Looking4Bargain
Looking4Bargain Nov. 18 at 2:00 PM
$PEN this will hit $320 next earnings - no stopping now.
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 13 at 3:37 PM
$PEN Share Price: $275.74 Contract Selected: Apr 17, 2026 $280 Calls Buy Zone: $18.79 – $23.21 Target Zone: $35.66 – $43.59 Potential Upside: 79% ROI Time to Expiration: 154 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
ZacksResearch
ZacksResearch Nov. 11 at 1:57 PM
$PEN keeps climbing! 🚀 Q3 adjusted EPS of 97 cents beat estimates by 7.78%, and revenues surged 17.8% year over year on a reported basis, propelling the stock up 20% since the announcement on Nov. 5. Impressive margin expansions and strong product sales are driving the momentum. 📈 Discover the full story here 👉 https://www.zacks.com/stock/news/2789089/penumbra-stock-up-post-q3-earnings-revenue-beat-margins-expand?cid=sm-stocktwits-2-2789089-body-20424&ADID=SYND_STOCKTWITS_TWEET_2_2789089_BODY_20424
0 · Reply
ZacksResearch
ZacksResearch Nov. 11 at 12:57 PM
$PEN surges after strong Q3 beat 🔥 Earnings and revenue both topped estimates, and the company’s margins expanded — signaling solid operational strength this quarter. See what’s driving the move higher 👉 https://www.zacks.com/stock/news/2789089/penumbra-stock-up-post-q3-earnings-revenue-beat-margins-expand?cid=sm-stocktwits-2-2789089-teaser-20404&ADID=SYND_STOCKTWITS_TWEET_2_2789089_TEASER_20404
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 9 at 10:47 PM
0 · Reply
BioTechHealthX
BioTechHealthX Nov. 8 at 3:50 PM
$PEN Penumbra jumps after Q3 2025 earnings beat; $355 M revenue and $1.17 EPS spark stronger 2026 forecasts. Click here to learn more! https://biotechhealthx.com/biotech-news/penumbra-pen-reports-355m-revenue-29-eps-beat/
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 10:01 PM
JP Morgan has updated their rating for Penumbra ( $PEN ) to Overweight with a price target of 275.
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 8:09 PM
Canaccord Genuity has adjusted their stance on Penumbra ( $PEN ), setting the rating to Buy with a target price of 350 → 355.
0 · Reply
IN0V8
IN0V8 Nov. 6 at 3:41 PM
$PEN Buy Jefferies raises target price to $335 from $325 JP Morgan raises target price to $275 from $265 Truist Securities raises target price to $312 from $300
0 · Reply
RenHenInvestments
RenHenInvestments Nov. 6 at 12:11 PM
$PEN Solid results, nice gap fill.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Nov. 6 at 12:05 PM
WATCHLIST NOV 06 2025 $XOM Exxon Mobil Expects First Gas From Offshore Greece Project Between 2030 And 2035 With Investment Of $50M To $100M $SLSR Solaris Resources Announce The Results Of A Pre-feasibility Study With An Updated Mineral Resource Estimate And Maiden Mineral Reserves For Its Warintza Project, Located In Southeastern Ecuador $PEN Penumbra shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates. $LTRX Needham Maintains Buy on Lantronix, Raises Price Target to $7.5 $LLY Eli Lilly' Phase 2 Trial For Obesity With At Least One Obesity-related Comorbidity And Without Type 2 Diabetes, Showed At 48 Weeks, All Treatment Arms Of Eloralintide Met The Primary Endpoint, Demonstrating Superior Mean Weight Reductions From 9.5% To 20.1% Compared To Placebo
0 · Reply
theflynews
theflynews Nov. 6 at 1:59 AM
Closing Bell Movers: Qualcomm down 3%, Robinhood slips 2% on earnings - $PEN - https://thefly.com/permalinks/entry.php/PENid4232011?1762393
0 · Reply